This brand name is authorized in Nigeria.
The drug KEMI contains a combination of these active pharmaceutical ingredients (APIs):
1
|
UNII
KGZ1SLC28Z - BECLOMETHASONE
|
|
Beclometasone is a pro-drug with weak glucocorticoid receptor binding affinity. It is extensively hydrolysed via esterase enzymes to the active metabolite beclometasone-17-monopropionate (B-17-MP), which has potent topical anti-inflammatory activity. |
|
2
|
UNII
G07GZ97H65 - CLOTRIMAZOLE
|
|
Clotrimazole acts against fungi by inhibiting ergosterol synthesis. Inhibition of ergosterol synthesis leads to structural and functional impairment of the fungal cytoplasmic membrane. Clotrimazole has a broad antimycotic spectrum of action in vitro and in vivo, which includes dermatophytes, yeasts, moulds, etc. |
|
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC Group | Classification | |
|---|---|---|
| D07CC04 | Beclometasone and antibiotics | D Dermatologicals → D07 Corticosteroids, dermatological preparations → D07C Corticosteroids, combinations with antibiotics → D07CC Corticosteroids, potent, combinations with antibiotics |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| NG | Registered Drug Product Database | 04-2034 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.